Patients See First Savings From Biden’s Drug Price Push, as Pharma Lines Up Its Lawyers
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Reporter Follows Up on ‘Cancer Moonshot’ Progress and the Bias in Digital Health Records
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
For Nursing Home Patients, Breast Cancer Surgery May Do More Harm Than Good
A new study of 6,000 older patients shows little gain from surgeries for breast cancer.
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
The costs of using a new class of cancer treatments include far more than the drug’s sticker price.
“¿Cuánto tiempo me queda, doctor?” Por qué muchos pacientes con cáncer no obtienen respuestas
Muchas veces los pacientes con cáncer no reciben respuestas adecuadas a preguntas críticas, entre ellas, la más crucial y universal de todas.
‘How Long Have I Got, Doc?’ Why Many Cancer Patients Don’t Have Answers
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
Widespread Hype Gives False Hope To Many Cancer Patients
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Nuevas drogas contra el cáncer, ¿ayudan a vivir más?
Empujados por defensores de pacientes que quieren acceso temprano a los medicamentos, la FDA ha aprobado una ráfaga de drogas oncológicas en los últimos años, Pero pocas de estas drogas han permitido a pacientes con una esperanza de vida limitada, vivir por años.
